Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries.

Autor: Seckinger A; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium.; Independent Myeloma Alliance, 8808 Pfäffikon, SZ, Switzerland., Salwender H; Department of Internal Medicine II, Asklepios Klinik Altona, 22763 Hamburg, Germany., Martin H; Department of Medicine, Hematology/Oncology, Goethe-University of Frankfurt, 60590 Frankfurt, Germany., Scheid C; Department I of Internal Medicine, University of Cologne, 50923 Köln, Germany., Hielscher T; Abteilung für Biostatistik, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany., Bertsch U; Medizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany., Hummel M; Abteilung für Biostatistik, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany., Jauch A; Institut für Humangenetik, Universität Heidelberg, 69120 Heidelberg, Germany., Knauf W; Onkologische Gemeinschaftspraxis, Agaplesion Bethanien Krankenhaus, 60389 Frankfurt, Germany., Emde-Rajaratnam M; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium., Beck S; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium., Neben K; Klinikum Mittelbaden, Medizinische Klinik 2, 76530 Baden-Baden, Germany., Dührig J; Katholisches Krankenhaus Hagen, 58099 Hagen, Germany., Lindemann W; Department of Hematology, University Hospital Essen, 45147 Essen, Germany., Schmidt-Wolf IGH; Department of Integrated Oncology, CIO Bonn, University of Bonn, 53127 Bonn, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz GmbH, 09113 Chemnitz, Germany., Blau IW; Medical Clinic III Hematology and Oncology, Charité University Medicine Berlin, 13353 Berlin, Germany., Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany., Weinhold N; Medizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany., Raab MS; Medizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany., Goldschmidt H; Medizinische Klinik V, Universitätsklinikum Heidelberg, 69120 Heidelberg, Germany.; Nationales Centrum für Tumorerkrankungen, 69120 Heidelberg, Germany., Choon-Quinones M; Independent Myeloma Alliance, 8808 Pfäffikon, SZ, Switzerland., Hose D; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), 1090 Jette, Belgium.; Independent Myeloma Alliance, 8808 Pfäffikon, SZ, Switzerland.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 11; Vol. 25 (12). Date of Electronic Publication: 2024 Jun 11.

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.

Autor: Stroh J; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Seckinger A; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Heider M; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Rudelius M; Institute of Pathology, Ludwigs Maximilians University, Munich, Germany., Eichner R; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany., Schick M; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany., Slawska J; Department of Medicine III, Klinikum rechts der Isar, and.; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany., Emde-Rajaratnam M; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Salwender H; Asklepios Tumorzentrum Hamburg, Hamburg, Germany.; AK Altona, Hamburg, Germany.; AK St. Georg, Hamburg, Germany., Bertsch U; Department of Internal Medicine V, and., Goldschmidt H; Department of Internal Medicine V, and.; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany., Weisel K; Department of Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Scheid C; Department of Internal Medicine I, and.; Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany., Keller U; Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin, Berlin, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and.; Max-Delbrück Center for Molecular Medicine, Berlin, Germany., Hose D; Department of Hematology and Immunology, Myeloma Center Brussels, and.; Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Bassermann F; Department of Medicine III, Klinikum rechts der Isar, and.; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany; and.

Publikováno v: Blood advances [Blood Adv] 2022 Jan 25; Vol. 6 (2), pp. 515-520.

Clinical bioinformatics desiderata for molecular tumor boards.

Autor: Pallocca, Matteo¹ (AUTHOR) matteo.pallocca@cnr.it, Betti, Martina² (AUTHOR), Baldinelli, Sara² (AUTHOR), Palombo, Ramona¹ (AUTHOR), Bucci, Gabriele³ (AUTHOR), Mazzarella, Luca^4,5 (AUTHOR), Tonon, Giovanni⁶ (AUTHOR), Ciliberto, Gennaro⁷ (AUTHOR)

Publikováno v: Briefings in Bioinformatics. Sep2024, Vol. 25 Issue 5, p1-9. 9p.

Actionable loss of SLF2 drives B‐cell lymphomagenesis and impairs the DNA damage response.

Autor: Zhang, Le, Wirth, Matthias, Patra, Upayan, Stroh, Jacob, Isaakidis, Konstandina, Rieger, Leonie, Kossatz, Susanne, Milanovic, Maja, Zang, Chuanbing, Demel, Uta, Keiten‐Schmitz, Jan, Wagner, Kristina, Steiger, Katja, Rad, Roland, Bassermann, Florian, Müller, Stefan, Keller, Ulrich, Schick, Markus

Publikováno v: EMBO Molecular Medicine; Sep2023, Vol. 15 Issue 9, p1-19, 19p